Butyrylcholinesterase (BChE) is an enzyme with broad substrate and ligand specificities and may function as a generalized bioscavenger by binding and/or hydrolyzing various xenobiotic agents and toxicants, many of which target the central and peripheral nervous systems. Variants of BChE were rationally designed to increase the enzyme’s ability to hydrolyze the psychoactive enantiomer of cocaine. These variants were cloned, and then expressed using the magnICON transient expression system in plants and their enzymatic properties were investigated. In particular, we explored the effects that these site-directed mutations have over the enzyme kinetics with various substrates of BChE. We further compared the affinity of various anticholinesterases including organophosphorous nerve agents and pesticides toward these BChE variants relative to the wild type enzyme. In addition to serving as a therapy for cocaine addiction-related diseases, enhanced bioscavenging against other harmful agents could add to the practicality and versatility of the plant-derived recombinant enzyme as a multivalent therapeutic.

Document Type


Publication Date


Notes/Citation Information

Published in Scientific Reports, v. 7, article no. 10419, p. 1-14.

© The Author(s) 2017

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

A correction to this article is available as an additional file listed below and online at https://doi.org/10.1038/s41598-018-35441-0.

Digital Object Identifier (DOI)


Funding Information

Work was supported in part by the National Institute for Drug Abuse Grant DP1 DA031340 awarded to the Mayo Clinic and subcontracted to ASU.

Related Content

All data generated or analyzed during this study are included in this published article (and its Supplementary Information files) except for the raw computational datasets that are available from the corresponding author on reasonable request.

Supplementary information accompanies this paper at doi: 10.1038/s41598-017-10571-z

41598_2017_10571_MOESM1_ESM.pdf (1381 kB)
Supplemental Tables, Figure Legends and Figures

s41598-018-35441-0.pdf (679 kB)
Author Correction